910543-72-5

Basic information

• Product Name: 3-AMINO-5-BROMO-1-METHYLPYRIDIN-2(1H)-ONE
• Synonyms: 3-AMINO-5-BROMO-1-METHYLPYRIDIN-2(1H)-ONE;3-Amino-5-bromo-1-methylp...;l-Methyl-3-aMino-5-broMo-l-H-pyridin-2-one;3-amino-5-bromo-1-methyl-1,2-dihydropyridin-2-one;3-amino-5-bromo-1-methyl-2(1H)-Pyridinone
• CAS NO: 910543-72-5
• Molecular Formula: C₆H₇BrN₂O
• Molecular Weight: 203.04
• Mol File: 910543-72-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 258.7±40.0 °C(Predicted)
• Appearance: /
• Density: 1.713±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2?+-.0.20(Predicted)
• CAS DataBase Reference: 3-AMINO-5-BROMO-1-METHYLPYRIDIN-2(1H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-5-BROMO-1-METHYLPYRIDIN-2(1H)-ONE(910543-72-5)
• EPA Substance Registry System: 3-AMINO-5-BROMO-1-METHYLPYRIDIN-2(1H)-ONE(910543-72-5)

Safety Data

• Hazardous Substances Data: 910543-72-5(Hazardous Substances Data)

Usage

Description

3-AMINO-5-BROMO-1-METHYLPYRIDIN-2(1H)-ONE is a chemical compound that serves as a crucial reagent in the synthesis of various pharmaceutical agents. It is characterized by its unique molecular structure, which includes an amino group, a bromine atom, and a methyl group attached to a pyridin-2(1H)-one core. 3-AMINO-5-BROMO-1-METHYLPYRIDIN-2(1H)-ONE plays a significant role in the development of potent inhibitors for specific biological targets, making it a valuable asset in medicinal chemistry.

Uses

Used in Pharmaceutical Industry:
3-AMINO-5-BROMO-1-METHYLPYRIDIN-2(1H)-ONE is used as a key intermediate in the synthesis of 5-phenylpyridin-2(1H)-one derivatives. These derivatives have demonstrated potent inhibitory activity against Bruton's tyrosine kinase (BTK), a critical enzyme involved in various inflammatory and immune responses. By targeting BTK, these derivatives have shown promise as effective treatments for rheumatoid arthritis, a chronic autoimmune disorder characterized by inflammation and pain in the joints.
In the development of antiarthritic agents, 3-AMINO-5-BROMO-1-METHYLPYRIDIN-2(1H)-ONE contributes to the creation of reversible BTK inhibitors. These inhibitors are designed to alleviate the symptoms of rheumatoid arthritis by modulating the immune system's response and reducing inflammation. The use of this compound in the synthesis of such inhibitors highlights its importance in advancing therapeutic options for patients suffering from this debilitating condition.
Furthermore, the versatility of 3-AMINO-5-BROMO-1-METHYLPYRIDIN-2(1H)-ONE as a reagent allows for the exploration of its potential applications in other areas of medicinal chemistry. Its unique structure and functional groups make it a promising candidate for the development of additional pharmaceutical agents targeting a variety of diseases and disorders. As research continues, the applications of this compound may expand, further solidifying its significance in the field of drug discovery and development.

Upstream product

• 14529-54-5 3,5-dibromo-1-methyl-1H-pyridin-2-one 
• 153888-45-0 5-bromo-1-methyl-3-nitropyridine-2(1H)-one 
• 1013-88-3 Benzophenone imine 
• 15862-34-7 5-bromo-3-nitro-1H-pyridin-2-one 
• 15862-34-7 5-bromo-3-nitro-2-pyridone 
• 1072-97-5 5-bromo-2-pyridylamine 

Downstream Products

• 1011797-06-0 N-[3-(5-amino-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-2-methyl-phenyl]-4-tert-butyl-benzamide 
• 1178884-09-7 6-(dimethylamino)-2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1198765-28-4 C₃₄H₃₄N₆O₅ 
• 1178884-20-2 6-tert-butyl-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one 
• 1198765-39-7 acetic acid 2(5-amino-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-6-(6-dimethylamino-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-benzyl ester 
• 1198765-36-4 C₁₄H₁₂BrN₃O₃S 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS BET INHIBITORS

Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.

Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition

Screening a 3-aminopyridin-2-one based fragment library against a 26-kinase panel representative of the human kinome identified 3-amino-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2(1H)-one (2) and 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one (3) as ligand efficient inhibitors of the mitotic kinase Monopolar Spindle 1 (MPS1) and the Aurora kinase family. These kinases are well recognised as attractive targets for therapeutic intervention for treating cancer. Elucidation of the binding mode of these fragments and their analogues has been carried out by X-ray crystallography. Structural studies have identified key interactions with a conserved lysine residue and have highlighted potential regions of MPS1 which could be targeted to improve activity and selectivity.

HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY

Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X, X, and Xare N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I foranddiagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.